Search Results for "Pharmac Cost Of Sativex In New Zealand"

22:28 EDT 29th May 2015 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

CombiCult

CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

New Zealand’s PHARMAC calls for information on anti-diabetic agents

New Zealand’s Pharmaceutical Management Agency, PHARMAC, today revealed it is interested in receiving…

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards (DHBs) over the next five years, says PHARMAC, New Zealand’s Pharmaceutical Management Agency...

PHARMAC in negotiations over rare disorders medicines

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is in active negotiations with several suppliers…

PHARMAC Stressing Biosimilar Use For Savings

In its annual review, the New Zealand pharmaceutical management agency PHARMAC says it has made substantial savings from switching to generics and is also now emphasizing the use of biosimilars.

NZ’s PHARMAC to fund Janssen prostate cancer drug

New Zealand’s Pharmaceuticals Management Agency PHARMAC will begin funding for the prostate cancer…

Savings from extended role exceed NZ$100 million, says NZ’s PHARMAC

District Health Boards are poised to save more than $100 million over five years as a result of New Zealand’s Pharmaceutical Management Agency PHARMAC’s expanded role, the agency reports in its An...

Hemophilia treatments funding proposal for New Zealand

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal involving…

'Surprise' Phase III failure of GW/Otsuka's Sativex in cancer pain

GW Pharmaceuticals is reeling on news that its cannabinoid-derived product Sativex has failed the first of three Phase III trials in the treatment of cancer pain. Sativex is licensed to Otsuka in the ...

Matching PubMed Articles

Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.

Objective Spending on medicines under the Pharmaceutical Benefits Scheme (PBS) represents the ninth largest expense to the Federal Government. A recent report by the Commission of Audit to the Federal...

Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!

Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sat...

Erratum to: Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex(®)) for Spasticity in Multiple Sclerosis.

A cost-benefit analysis of pre- and post-lambing anthelmintic treatments to twin-bearing ewes on commercial farms in the southern North Island of New Zealand.

Abstract AIM: To conduct a cost-benefit analysis of the administration of anthelmintics to adult ewes around lambing.

Assessment of the effectiveness and safety of Sativex ® in compassionate use.

INTRODUCTION. Sativex ® is a drug approved for use in the treatment of spasticity in multiple sclerosis. We sought to study the tolerability and effectiveness of this drug product in pathologies beyo...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement